Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment

Patients with hematologic malignancies are well known to have prolonged COVID-19 pneumonia. The cause has been reported to be B cell depletion after administration of anti-CD20 antibodies. Here, we report a case of COVID-19 pneumonia due to prolonged B-cell depletion after anti-CD20 antibody therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Murase, Kazuyuki, Takada, Kohichi, Arihara, Yohei, Miyanishi, Koji, Kato, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404336/
https://www.ncbi.nlm.nih.gov/pubmed/37551219
http://dx.doi.org/10.7759/cureus.41486
_version_ 1785085276628975616
author Murase, Kazuyuki
Takada, Kohichi
Arihara, Yohei
Miyanishi, Koji
Kato, Junji
author_facet Murase, Kazuyuki
Takada, Kohichi
Arihara, Yohei
Miyanishi, Koji
Kato, Junji
author_sort Murase, Kazuyuki
collection PubMed
description Patients with hematologic malignancies are well known to have prolonged COVID-19 pneumonia. The cause has been reported to be B cell depletion after administration of anti-CD20 antibodies. Here, we report a case of COVID-19 pneumonia due to prolonged B-cell depletion after anti-CD20 antibody therapy for malignant lymphoma two years before. Sotrovimab, a neutralizing antibody that was designed to prevent the progression of COVID-19, was successful in preventing the progression to severe disease in this B-cell-depleted patient.
format Online
Article
Text
id pubmed-10404336
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-104043362023-08-07 Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment Murase, Kazuyuki Takada, Kohichi Arihara, Yohei Miyanishi, Koji Kato, Junji Cureus Infectious Disease Patients with hematologic malignancies are well known to have prolonged COVID-19 pneumonia. The cause has been reported to be B cell depletion after administration of anti-CD20 antibodies. Here, we report a case of COVID-19 pneumonia due to prolonged B-cell depletion after anti-CD20 antibody therapy for malignant lymphoma two years before. Sotrovimab, a neutralizing antibody that was designed to prevent the progression of COVID-19, was successful in preventing the progression to severe disease in this B-cell-depleted patient. Cureus 2023-07-06 /pmc/articles/PMC10404336/ /pubmed/37551219 http://dx.doi.org/10.7759/cureus.41486 Text en Copyright © 2023, Murase et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Infectious Disease
Murase, Kazuyuki
Takada, Kohichi
Arihara, Yohei
Miyanishi, Koji
Kato, Junji
Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment
title Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment
title_full Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment
title_fullStr Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment
title_full_unstemmed Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment
title_short Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment
title_sort sotrovimab treatment for covid-19 effective in a b-cell-depleted patient after anti-cd20 treatment
topic Infectious Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404336/
https://www.ncbi.nlm.nih.gov/pubmed/37551219
http://dx.doi.org/10.7759/cureus.41486
work_keys_str_mv AT murasekazuyuki sotrovimabtreatmentforcovid19effectiveinabcelldepletedpatientafteranticd20treatment
AT takadakohichi sotrovimabtreatmentforcovid19effectiveinabcelldepletedpatientafteranticd20treatment
AT ariharayohei sotrovimabtreatmentforcovid19effectiveinabcelldepletedpatientafteranticd20treatment
AT miyanishikoji sotrovimabtreatmentforcovid19effectiveinabcelldepletedpatientafteranticd20treatment
AT katojunji sotrovimabtreatmentforcovid19effectiveinabcelldepletedpatientafteranticd20treatment

Ejemplares similares